

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Vanguard CPV suspension for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 1 ml dose contains:

Active substance:

Canine parvovirus, strain NL-35-D, live, low passage, minimum: $10^{7.0}$ CCID₅₀*

*Cell culture infectious dose 50%

Excipients:

Qualitative composition of excipients and other constituents
Gentamycin
Neomycin

Clear to slightly turbid reddish liquid.

3. CLINICAL INFORMATION

3.1 Target species

Dogs.

3.2 Indications for use for each target species

Active immunisation of dogs to prevent clinical signs including leucopenia and reduce viral shedding caused by canine parvovirus (type 2a), and to prevent mortality and clinical signs including leucopenia and reduce viral shedding caused by canine parvovirus (types 2b and 2c).

Onset of immunity occurs by approximately two weeks after the last dose of the Basic Vaccination Schedule. Onset of immunity for the canine parvovirus component (type 2b) occurs 7 days after a single dose when animals are vaccinated from 9 weeks of age.

Duration of immunity: 12 months.

3.3 Contraindications

None.

3.4 Special warnings

Vaccinate healthy animals only.

The canine parvovirus vaccinal strains may be shed from vaccinated animals for a number of days following vaccination. However, due to the low pathogenicity of this strain, it is not necessary to keep vaccinated animals separated from non-vaccinated animals.

High levels of maternally derived antibodies (MDA) may interfere with the response to vaccination. Although the vaccine has been shown to be efficacious in the presence of levels of MDA that are likely to be encountered under field conditions, where for any reason it is likely that particularly high levels of MDA against CPV are present, this should be taken into account when planning the timing of vaccinations.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs.

Common (1 to 10 animals / 100 animals treated):	Injection site swelling ¹
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Anaphylaxis (e.g. vomiting) ²

¹ Transient. May occur 4-6 hours after vaccination, resolves after approximately 7 days.

² If such reaction occurs, administer adrenaline or an equivalent.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy:

Do not use during pregnancy.

3.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product, except when used with vaccines from the Vanguard range containing canine distemper virus, canine adenovirus, canine parainfluenza virus or leptospira antigens. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis.

3.9 Administration routes and dosage

Dosage and route of administration:

Shake well and immediately inject the entire contents of the vial (1 ml) subcutaneously.

Basic Vaccination Schedule:

Puppies younger than 10 weeks of age

Two doses of Vanguard CPV at least 14 days apart. The first dose can be given as young as 6 weeks of age. The second dose should not be given until at least 10 weeks of age.

Puppies 10 weeks of age and older

A single dose of Vanguard CPV

Re-vaccination Schedule:

A single dose of Vanguard CPV to be given annually thereafter.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

No adverse events other than those mentioned in section 3.6 have been observed following administration of a 10-fold overdose.

No treatment is necessary in most cases of overdose. However, if a systemic anaphylactic reaction occurs (e.g., vomiting), administer adrenaline or an equivalent.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. IMMUNOLOGICAL INFORMATION

4.1 ATCvet code: QI07AD01

The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by canine parvovirus.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Do not mix with any other veterinary medicinal product.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 4 years.

5.3 Special precautions for storage

Store and transport refrigerated (2 °C - 8 °C).
Do not freeze.

5.4 Nature and composition of immediate packaging

The vaccine is filled in 1 dose vials glass Type I (Ph. Eur.), closed with a chlorobutyl rubber stopper and a varnished aluminium cap.

Pack contains 1, 10, 25 or 100 vials of 1 ml Vanguard CPV.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis Belgium S.A.

7. MARKETING AUTHORISATION NUMBER

Vm 60021/3026

8. DATE OF FIRST AUTHORISATION

28 October 2005

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

August 2025

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription.

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

Gavin Hall

Approved: 19 December 2025